Royalty Pharma (RPRX) announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman. Ashwin joins Royalty Pharma from Morgan Stanley (MS) where he was a Managing Director and Head of West Coast Biotechnology Investment Banking.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RPRX:
- Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
- Royalty Pharma sees FY23 adjusted cash receipts view $2.375B-$2.475B
- Royalty Pharma reports Q4 revenue $566M vs $576M last year
- Royalty Pharma Reports Q4 and Full Year 2022 Results
- Royalty Pharma to Present at Upcoming Investor Conferences